Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design

References

• Abd TT, Jacobson TA. (2011). Statin-induced myopathy: a review and update. Expert Opin Drug Saf 10:373–387.
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists’ (CTT) Collaborators. (2005). Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Chu ZL, Carroll C, Alfonso J, Gutierrez V, He H, Lucman A, Pedraza M, Mondala H, Gao H, Bagnol D, Chen R, Jones RM, Behan DP, Leonard J. (2008). A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology 149:2038–2047.
   PubMed Web of Science ®Google Scholar
• Conforti A, Chiamulera C, Moretti U, Colcera S, Fumagalli G, Leone R. (2007). Musculoskeletal adverse drug reactions: a review of literature and data from ADR spontaneous reporting databases. Curr Drug Saf 2:47–63.
   Google Scholar
• Crestor (rosuvastatin calcium) Label. FDA Drug Label. (2012) http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021366Orig1s024Lbl.pdf
   Google Scholar
• Florentin M, Elisaf MS. (2012). Simvastatin interactions with other drugs. Expert Opin Drug Saf 11:439–444.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. (2012) Guidance for Industry Drug Interaction Studies - Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf
   Google Scholar
• Generaux GT, Bonomo FM, Johnson M, Doan KM. (2011). Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins. Xenobiotica 41:639–651.
   PubMed Web of Science ®Google Scholar
• Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9:215–236.
   PubMed Web of Science ®Google Scholar
• Hauschke D, Steinijans VW, Diletti E. (1990). A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 28:72–78.
   PubMed Web of Science ®Google Scholar
• Jones RM, Leonard JN, Buzard DJ, Lehmann J. (2009). GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat 19:1339–1359.
   PubMed Web of Science ®Google Scholar
• Katz LB, Gambale JJ, Rothenberg PL, Vanapalli SR, Vaccaro N, Xi L, Sarich TC, Stein PP. (2012). Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes Metab 14:709–716.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, Niemi M. (2008). ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 84:457–461.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. (2009a). Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10:1617–1624.
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. (2009b). ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 86:197–203.
   PubMed Web of Science ®Google Scholar
• Levien TL, Baker DE. (2009). New Drugs in Development for the Treatment of Diabetes. Diabetes Spectrum 22, 92–106.
   Google Scholar
• Mathers CD, Boerma T, Ma Fat D. (2009). Global and regional causes of death. Br Med Bull 92:7–32.
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Backman JT, Niemi M. (2008). Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 47:463–474.
   PubMed Web of Science ®Google Scholar
• Niemi M. (2010). Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther 87:130–133.
   PubMed Web of Science ®Google Scholar
• Nunez DJ, Bush MA, Collins DA, McMullen SL, Apseloff G, Cosino L, Morrow L, Feldman PL. (2012). Effects on Lipids of GSK1292263, a GPR119 Agonist, in Type 2 Diabetics. Diabetes 61, 1084-P.
   Google Scholar
• Nunez DJ, Bush MA, Collins DA, McMullen SL, Feldman PL, Jackson TD, Ross SA. (2011). Evaluation of GSK1292263, a Novel GPR119 Agonist, in Type 2 Diabetes Mellitus (T2DM): Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses. Diabetes 60, 996-P.
   Google Scholar
• Nunez DJ, Lewis EW, Swan S, Bush MA, Cannon C, McMullen SL, Collins DA, Feldman PL. (2010). A Study in Healthy Volunteers To Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Doses of GSK1292263, a Novel GPR119 Agonist. Diabetes 58, 80-OR.
   Google Scholar
• Ohishi T, Yoshida S. (2012). The therapeutic potential of GPR119 agonists for type 2 diabetes. Expert Opin Investig Drugs 21:321–328.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. (2007). Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 82:726–733.
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics 16:873–879.
   PubMed Web of Science ®Google Scholar
• Polli JW, Humphreys JE, Harmon KA, Castellino S, O’Mara MJ, Olson KL, John-Williams LS, Koch KM, Serabjit-Singh CJ. (2008). The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 36:695–701.
   PubMed Web of Science ®Google Scholar
• Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. (2006). In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos 34:786–792.
   PubMed Web of Science ®Google Scholar
• Zocor (simvastatin) Drug Label. FDA Drug Label. (2012). http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/019766s085lbl.pdf
   Google Scholar